However, given that plasma adverse effects are very unlikely following the recommended procedures for obtaining and administering it, and given the benefits of its administration, and more specifically, of its early administration in B-cell-depleted patients, as can be seen in the many cases of persisting COVID-19 that were cured with CP after its administration, there is good evidence on the use of CP to treat immunocompromised patients with COVID-19 [62,65,66]. Here, CP is linked to COVID-19.